Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer

Table 1

Basic characteristics of included literature.

Author (years)	Age (years)	Research objects	Sample size ()	Intervention measures of experimental group	Outcome indicators
Zheng et al. [10]	18-75	AGC	49/48	Therapeutic effect of	①②③④⑤⑧⑨⑩
Fan [11],		AGC	40/40	Therapeutic effect of	①②③⑨⑩
Ma et al. [12]	18-75	MGC	23/23	Therapeutic effect of	①②③
Li et al. [13]	18-75	AGC	20/20	Therapeutic effect of	①②③
Wang [14],	≥18	First line and above AGC	29/29	AGC effect of	①②③
Wei et al. [15]	30-74	First line and above AGC	24/24	Therapeutic effect of 250 mg	①②③④⑥
Jing et al. [16]	18-80	First line and above AGC	40/40	Therapeutic effect of	①②③
Peng et al. [17]	≥18	First line and above AGC	30/30	Therapeutic effect of	①②③⑧
Wang et al. [18]	18-75	AGC	32/32	Therapeutic effect of	①②③
Shao and Xu [19]	≥18	AGC	15/15	Therapeutic effect of	①②③④⑦⑧⑨⑩
Liang [20]	≥18	AGC	20/20	Therapeutic effect of	①②③⑧
Deng et al. [21]	≥18	AGC	14/14	Therapeutic effect of	①②③
Tang et al. [22]	18-75	First line and above AGC	15/15	Therapeutic effect of	①②③
Huang et al. [23]	≥18	AGC	16/15	Therapeutic effect of	①②③
Kuang [24],	18-80	AGC	26/26	Therapeutic effect of Chinese medicine	①②③
Tang et al. [25]	≥18	First line and above AGC	75/75	Therapeutic effect of	①②③
Kawazoe et al. [26]	≥20	AGC	30/30	Therapeutic effect of	①②③
Xu et al. [27]	≥18	AGC	23/23	Therapeutic effect of	①②③
Yan et al. [28]	≥18	First line and above AGC	34/34	Therapeutic effect of	①②③
Xu et al. [29]	≥18	AGC	21/21	Therapeutic effect of	①②③

Note: ①: DCR: disease control rate; ②: ORR: objective remission rate; ③: related adverse reactions; ④: Th1 (IFN-γ, TNF-α); ⑤: Th2 (IL-10, IL-6); ⑥: Th2 (IL-19, IL-4); ⑦: Th2 (IL-10, IL-4); ⑧: relevant tumor markers; ⑨: median PFS: median progression-free survival; ⑩: median OS: median overall survival.